RSV vaccine recommendations change

#MiddleburyCT #RSVVaccine

The vaccine for RSV (respiratory syncytial virus) has come under some changes in the CDC recommendations list. Until recently, they suggested that anyone over 60 should consider getting the vaccine.

Now they say, specifically:

• If you’re over 75, get the shot.
• If you’re between 60 and 74, get the shot if you’re at risk of contracting a severe case of RSV. Those most at risk include those with a chronic condition such as lung disease, diabetes, liver disorders and more.
• If you’re between 50 and 59, one of the two versions of the vaccine is suitable for you if you run the risk of severe RSV.

In other words, if you’re at risk, you move to the head of the priority line. RSV causes lower respiratory tract disease, and the shots have an 80% efficacy rate, which means they will likely help. These suggestions are for those who didn’t get the vaccine last year (the first year the vaccine was available); you don’t need one every year.

Step one would be to ask your doctor if you should get the vaccine. If the answer is yes, ask if there is a preference between the two (Arexvy vs. Pfizer). Ask when you should get it. The CDC recommends late summer and early fall, before the RSV season hits.

At this point, the CDC is looking at studies to decide whether additional doses are needed in seniors, especially considering the potential side effects that popped up in clinical trials. Specifically, the CDC, as well as the FDA, are monitoring the data to see if there is a possibility of increased risk of Guillain-Barré syndrome (GBS) with the RSV vaccine. That is likely the reason for the change from “everyone over age 60” should consider getting the vaccine to “those who are at the highest risk” for severe RSV disease.

© 2024 King Features Synd., Inc.